Navigation Links
Alere Inc. Announces Tender Offer and Consent Solicitation for Any and All of its 9.00% Senior Subordinated Notes due 2016
Date:5/10/2013

WALTHAM, Mass., May 10, 2013 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company") announced today that it has commenced a cash tender offer for any and all of its outstanding $400 million aggregate principal amount of 9.00% Senior Subordinated Notes due 2016 (the "Notes") (CUSIP No. 01449JAB1).  The Company also announced a concurrent consent solicitation for the adoption of proposed amendments to the indenture dated as of May 12, 2009 among the Company, U.S. Bank National Association (the "Trustee") and certain guarantors named therein (as amended, supplemented or otherwise modified prior to the date hereof, the "Indenture"), under which the Notes were issued. The tender offer and the consent solicitation are being made on the terms and subject to the conditions set forth in the Offer to Purchase and Consent Solicitation Statement dated May 10, 2013 (the "Offer to Purchase").  Holders that tender their Notes pursuant to the tender offer prior to the Withdrawal Deadline (as defined in the Offer to Purchase) will be deemed to have consented to the proposed amendments to the Indenture.

The offer to purchase will expire at 11:59 p.m., New York City time, on June 7, 2013 unless extended or earlier terminated (such time and date, as the same may be extended, the "Expiration Date"). Holders of Notes ("Holders") must tender their Notes and provide their consents to the amendments to the Indenture before 5:00 p.m., New York City time, on May 23, 2013 (the "Consent Date") in order to be eligible to receive the Total Consideration (as defined below).  Holders who tender their Notes after the Consent Date and before the Expiration Date will only be eligible to receive the Tender Offer Consideration (as defined below).

The tender offer and consent solicitation are subject to the sati
'/>"/>

SOURCE Alere Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alere Acquires Epocal, Inc.
2. Alere Inc. Announces Hiring of Namal Nawana as Chief Operating Officer
3. Alere Inc. Announces Early Results of its Tender Offer and Consent Solicitation for Any and All of its 7.875% Senior Notes due 2016
4. Alere Inc. Announces Offering of $450 Million of Senior Notes
5. Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal
6. Telik Announces First Quarter 2013 Financial Results
7. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc.
8. Bernstein Liebhard LLP Announces That A Securities Class Action Has Been Filed Against Aveo Pharmaceutical, Inc.
9. Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
10. Echo Therapeutics Announces First Quarter 2013 Financial Results
11. Life Care Medical Devices Ltd Announces Addition Of Dublin, Ireland Based European Subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 TWi Biotechnology, Inc., today ... for AC-201, TWi Biotechnology,s lead drug candidate, from ... China for patent application numbered 201180018154.8.  ... salts, active metabolite for treatment of type II ... treatment using AC-201 for type II diabetes, and ...
(Date:12/19/2014)... December 19, 2014 TODAY, AEGATE, ... the World announced the appointment of Peter Fox ... as Chief Channels and Partner Officer. Peter ... through to its acquisition by Oracle in 2011. ... Geneva and subsequently Convergys, a ...
(Date:12/19/2014)... 19, 2014 You,re visiting the dentist for ... when he or she says you need a root ... you may have several questions and feel apprehensive about ... know it,s nothing to worry about. The Pennsylvania Dental ... alleviate any anxiety the public may have surrounding this ...
Breaking Medicine Technology:TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Root Canals Have Become More Routine 2
... 31 Eli Lilly and Company announced today that ... GEMZAR(R) (gemcitabine HCl for injection) to the current standard ... survival at three years for women with locally advanced ... most commonly diagnosed women,s cancer, and the second most ...
... III ZODIAC study in advanced non-small cell lung cancer ... at the American Society of Clinical Oncology (ASCO) meeting ... primary endpoint, demonstrating that the addition of vandetanib to ... survival (PFS), the length of time a patient lives ...
Cached Medicine Technology:Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 2Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 3Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 4Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 5Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 6Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 2Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 3Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 4Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 5
(Date:12/22/2014)... Only weeks following the announcement that Henderson, Nevada ... a battery manufacturer create 29 well-paying jobs in Mojave ... launching in Henderson to deliver yet another win ... sector is going to build a stronger middle class ... works with small businesses that rely on middle class ...
(Date:12/22/2014)... December 22, 2014 In recognition of ... sales to Hero Reward, a local organization that provides ... , Located on a couple hundred acres ... Program offers lodging, world class fishing, hunting, hiking, horseback ... was founded several years ago to support U.S. Service ...
(Date:12/22/2014)... Pasadena sleep apnea dentist, ... apnea. Drowsy drivers are 15 times more likely to ... and some experts believe that sleep-deprived drivers may be ... Unfortunately, millions of Americans may be sleep-deprived without even ... Medicine, about 18 million Americans have sleep apnea, but ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again ... provide logistics and support for one of Dallas’ largest holiday ... history of giving back to the community in which it ... Drive were Whataburger® and 99.5 The Wolf. , There is ... gifts to children who would otherwise not receive any is ...
Breaking Medicine News(10 mins):Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2
... discovered an accomplice in breast cancer a master control ... reactions orchestrated by a cancer-causing gene (or oncogene) named Wnt1. ... back-to-back papers featured on the cover of the August 15 ... about the regulation of a Wnt oncogene," explains lead author ...
... By Jenifer Goodwin HealthDay Reporter , ... mistakes, admitting the error, saying "I,m sorry" and offering ... lawsuits, new research shows. In 2001, University ... workers to report medical mistakes. The program included a ...
... Supports (CLASS) Act a largely overlooked component of the ... potential to transform long-term care financing in the United States ... latest issue of Public Policy & Aging Report ... The SCAN Foundation , this installment of PPAR ...
... This release is available in French . ... boys with low parental monitoring are more likely to befriend ... to a new study published in the journal Addictive ... de Montral and Sainte-Justine University Hospital Research Center found that ...
... fellow Amy Speed-Andrews has examined how a specialized Iyengar yoga ... who have completed treatment, makes a difference in their recovery. ... to fill out a questionnaire about their physical and mental ... yoga and again at the end. After analyzing the data ...
... are developing the first device able to transmit American ... just completing its initial field test by participants in ... "This is the first study of how deaf people ... project leader Eve Riskin, a UW professor of electrical ...
Cached Medicine News:Health News:Researchers identify breast cancer culprits 2Health News:When Doctors Admit Mistakes, Fewer Malpractice Suits Result, Study Says 2Health News:When Doctors Admit Mistakes, Fewer Malpractice Suits Result, Study Says 3Health News:CLASS Act analysis reveals America's long-term care future 2Health News:Heavy drug-use among bad boys curbed by parental monitoring and peers 2Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 2Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 3
... Delivery System (CDS) facilitates the ... the Aescula LV Left-Heart Lead. ... patented coronary sinus curve that ... access to the coronary sinus ...
... PCS2 system is Haemonetics ... collection of plasma and ... the collection of "jumbo" ... platelet-poor plasma with optional ...
Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
... provides quick, convenient, repetitive dispensing for ... have a polyethylene plunger and a ... use with most reagents. Application: ... separate volumes can be selected for ...
Medicine Products: